Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Japan”

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)Recruiting
NCT07361510Phase 3Updated Aug 10, 2026
Sponsor: Bristol-Myers Squibb
Non-Small Cell Lung Cancer (NSCLC)
United States, Argentina, Australia, Austria, Belgium +31 more
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)Recruiting
NCT06926868Phase 2, Phase 3Updated Aug 10, 2026
Sponsor: Bristol-Myers Squibb
Breast Neoplasms
United States, Argentina, Australia, Austria, Brazil +23 more
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer DrugsRecruiting
NCT07336446Phase 1, Phase 2Updated Aug 10, 2026
Sponsor: AstraZeneca
Prostate Cancer
United States, Australia, Canada, China, Japan +3 more
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionRecruiting
NCT07063745Phase 2, Phase 3Updated Aug 10, 2026
Sponsor: Bristol-Myers Squibb
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
United States, Argentina, Australia, Austria, Belgium +29 more
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye DiseaseActive Not Recruiting
NCT06401044Phase 1, Phase 2Updated Aug 10, 2026
Sponsor: Amgen
Thyroid Eye Disease
United States, Australia, Canada, France, Germany +7 more
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)Completed
NCT05153239Phase 3Updated Aug 10, 2026
Sponsor: PharmaMar
Relapsed Small Cell Lung Cancer
United States, Australia, Austria, Belgium, Brazil +19 more
Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)Terminated
NCT06161116Phase 2Updated Aug 10, 2026
Sponsor: Merck Sharp & Dohme LLC
Systemic Lupus Erythematosus
United States, Argentina, Brazil, Canada, Chile +12 more
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Active Not Recruiting
NCT05952557Phase 3Updated Aug 10, 2026
Sponsor: AstraZeneca
Breast Cancer, Early Breast Cancer
United States, Argentina, Australia, Austria, Belgium +39 more
Feasibility Trial of Functional Clothing, Moderate Exercise, and Health Information for Stress Reduction and Behavior Change in OkinawaCompleted
NCT07204483NAUpdated Aug 10, 2026
Sponsor: Shinyu Kise
Obesity · Metabolic Syndrome · Stress, Psychological
Japan
A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)Recruiting
NCT07340827Phase 3Updated Aug 10, 2026
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Infertility
Japan
A Trial of Setmelanotide in Acquired Hypothalamic ObesityActive Not Recruiting
NCT05774756Phase 3Updated Aug 10, 2026
Sponsor: Rhythm Pharmaceuticals, Inc.
Hypothalamic Obesity
United States, Canada, Germany, Japan, Netherlands +1 more
Study of ALXN2220 Versus Placebo in Adults With ATTR-CMActive Not Recruiting
NCT06183931Phase 3Updated Aug 10, 2026
Sponsor: Alexion Pharmaceuticals, Inc.
Transthyretin Amyloid Cardiomyopathy
United States, Argentina, Australia, Austria, Belgium +22 more
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)Recruiting
NCT07405164Phase 3Updated Aug 10, 2026
Sponsor: Merck Sharp & Dohme LLC
Von Hippel-Lindau Disease · Malignant Neoplasms
United States, Australia, Belgium, Brazil, Chile +16 more
Injured Submucosal Arteries After CSP for 10-19 mm Nonpedunculated Colorectal Polyps.Active Not Recruiting
NCT05930041NAUpdated Aug 10, 2026
Sponsor: Showa Inan General Hospital
Colonic Polyp
Japan
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsActive Not Recruiting
NCT05936359Phase 1Updated Aug 10, 2026
Sponsor: Incyte Corporation
Myeloproliferative Neoplasms
Australia, Canada, Denmark, France, Germany +4 more
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C MutationRecruiting
NCT05789082Phase 1, Phase 2Updated Aug 10, 2026
Sponsor: Hoffmann-La Roche
Non-Small Cell Lung Cancer
United States, Argentina, Australia, Belgium, Brazil +13 more
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.Recruiting
NCT07146906Phase 2Updated Aug 10, 2026
Sponsor: Novartis Pharmaceuticals
Immunoglobulin A Nephropathy (IgAN)
United States, Brazil, China, Czechia, Germany +6 more
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated RegimenActive Not Recruiting
NCT05502341Phase 2, Phase 3Updated Aug 10, 2026
Sponsor: Gilead Sciences
HIV-1-infection
United States, Argentina, Australia, Canada, Dominican Republic +10 more
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not WorkActive Not Recruiting
NCT06290128Phase 3Updated Aug 10, 2026
Sponsor: Sanofi
Chronic Inflammatory Demyelinating Polyradiculoneuropathy · Polyneuropathy, Inflammatory Demyelinating, Chronic
United States, Argentina, Belgium, Brazil, Bulgaria +19 more
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia AreataTerminated
NCT06444451Phase 2Updated Aug 10, 2026
Sponsor: Sanofi
Alopecia Areata
United States, Argentina, Australia, Bulgaria, Canada +11 more
An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care TreatmentActive Not Recruiting
NCT06883240N/AUpdated Aug 10, 2026
Sponsor: Hoffmann-La Roche
Von Willebrand Disease, Type 3
United States, Belgium, Canada, Colombia, France +9 more
First-in-Human Trial of DS1025a in Participants With Advanced Solid TumorsRecruiting
NCT07681882Phase 1Updated Aug 10, 2026
Sponsor: Daiichi Sankyo
Advanced Solid Tumor · Metastatic Solid Tumor · Unresectable Solid Tumor
Japan
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 DiabetesRecruiting
NCT07415954Phase 2Updated Aug 10, 2026
Sponsor: Novo Nordisk A/S
Diabetes Mellitus, Type 2
United States, Croatia, Hungary, Japan, Poland +5 more
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque PsoriasisCompleted
NCT06586112Phase 3Updated Aug 10, 2026
Sponsor: Alumis Inc
Plaque Psoriasis
United States, Australia, Bulgaria, Canada, Czechia +5 more
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)Recruiting
NCT06943872Phase 3Updated Aug 10, 2026
Sponsor: BeOne Medicines
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
United States, Argentina, Australia, Austria, Belgium +16 more

Previous page Next page